Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/27/2023* -- Earnings Call Q4 2022 -- -- --
02/27/2023* -- Results Q4 2022 -- -0.05 --
11/03/2022 16:30 EST Earnings Call Q3 2022 -- -- --
11/03/2022 -- Results Q3 2022 -0.05 -0.05 0.00%
08/04/2022 16:30 EST Earnings Call Q2 2022 -- -- --
08/04/2022 -- Results Q2 2022 -0.06 -0.06 5.26%
05/05/2022 16:30 EST Earnings Call Q1 2022 -- -- --
05/05/2022 -- Results Q1 2022 -0.07 -0.08 16.00%
*Estimated Date/Time

Earnings

Next Report Date 02/27/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/03/2022
Beat/Miss Upgrade
Return Since -3.85%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
URL http://www.cerus.com
Investor Relations URL https://ir.cerus.com/
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style Small Cap/Blend
Next Earnings Release Feb. 27, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
-31.17%
-22.30%
50.00%
-16.77%
63.98%
-1.59%
-46.40%
-10.96%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
7.86%
-38.13%
-31.16%
-24.87%
108.1%
-27.93%
-13.82%
-36.28%
62.28%
-78.57%
4.09%
-76.55%
-0.62%
-24.70%
-53.18%
17.86%
3.12%
-47.58%
48.46%
17.10%
-95.00%
-57.48%
77.60%
-68.73%
117.2%
--
--
--
-85.79%
-73.70%
-79.00%
-92.45%
-48.39%
As of February 03, 2023.

Profile

Edit
Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
URL http://www.cerus.com
Investor Relations URL https://ir.cerus.com/
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style Small Cap/Blend
Next Earnings Release Feb. 27, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
RBF20927 3.894M USD 2.94%
EARK.NO 418803.0 USD 0.69%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter CERS Tweets